Imunon (Imunon) GF Value : $4.07 (As of Apr. 30, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Imunon GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-30), Imunon's share price is $1.31. Imunon's GF Value is $4.07. Therefore, Imunon's Price-to-GF-Value for today is 0.32.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Imunon is Possible Value Trap, Think Twice.

Imunon (NAS:IMNN) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Imunon's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.31	/	4.07
	=	0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon GF Value Related Terms

Thank you for viewing the detailed overview of Imunon's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon (Imunon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Executives

James E Dentzer	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne	director, officer: President and CEO	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno	officer: Chief Executive Offier	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John	officer: Chief Accounting Officer	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg	director	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church	officer: Chief Financial Officer
Robert W Hooper	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc.	10 percent owner	601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer	officer: Chief Scientific Officer	C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107